Sigilon Therapeutics, Inc.
SGTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $13 | $10 | $13 | $14 |
| % Growth | 34.8% | -28.2% | -5.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $13 | $10 | $13 | $14 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $38 | $65 | $53 | $48 |
| G&A Expenses | $19 | $20 | $13 | $10 |
| SG&A Expenses | $19 | $20 | $13 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $57 | $85 | $66 | $58 |
| Operating Income | -$44 | -$76 | -$53 | -$44 |
| % Margin | -337.3% | -788% | -393.6% | -311.7% |
| Other Income/Exp. Net | $0 | -$2 | -$2 | $0 |
| Pre-Tax Income | -$44 | -$77 | -$55 | -$44 |
| Tax Expense | -$0 | $1 | $0 | $1 |
| Net Income | -$43 | -$78 | -$55 | -$45 |
| % Margin | -335.7% | -815% | -410.3% | -314.9% |
| EPS | -1.34 | -31.92 | -22.67 | -27.53 |
| % Growth | 95.8% | -40.8% | 17.7% | – |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 |
| Weighted Avg Shares Out | 32 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 32 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $1 |
| Interest Expense | $2 | $2 | $1 | $1 |
| Depreciation & Amortization | $2 | $0 | $0 | $2 |
| EBITDA | -$39 | -$75 | -$53 | -$42 |
| % Margin | -300.3% | -781.4% | -397.7% | -299.5% |